SELLAS Life Sciences Group Inc sell mixitrader
Start price
12.12.20
/
50%
€6.60
Target price
12.12.21
€3.00
Performance (%)
63.18%
End price
26.06.21
€10.77
Summary
This prediction ended on 26.06.21 with a price of €10.77. The price for SELLAS Life Sciences Group Inc massively increased, which is bad news for the SELL prediction by mixitrader. mixitrader has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 6.250% | 6.250% | 694.964% | 684.801% |
| iShares Core DAX® | 0,44 % | 5,90 % | 8,05 % | 65,58 % |
| iShares Nasdaq 100 | 1,06 % | 0,92 % | 28,47 % | 90,18 % |
| iShares Nikkei 225® | 1,77 % | 1,23 % | 47,57 % | 84,99 % |
| iShares S&P 500 | 0,37 % | 1,92 % | 23,20 % | 70,76 % |